Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients treated with Vectibix™ (panitumumab)

GlaxoSmithKline (GSK) would like to inform healthcare professionals of the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with Vectibix™ (panitumumab). Based on data from a regular safety review, rare (≥1/10,000 to <1/1000 patients) cases of SJS and TEN have been reported in patients treated with Vectibix™. Healthcare professionals are advised to withhold or discontinue the use of Vectibix™ in their patients if SJS or TEN are suspected.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.